Abstract: Recombinant influenza virus proteins, including influenza capsomers, subviral particles, virus-like particles (VLP), VLP complexes, and/or any portions of thereof, are provided as a vaccine for influenza viruses. The invention is based on the combination of two vaccine technologies: (1) intrinsically safe recombinant vaccine technology, and (2) highly immunogenic, self-assembled protein macromolecules embedded in plasma membranes and comprised of multiple copies of influenza virus structural proteins exhibiting neutralizing epitopes in native conformations.

Abstract: A recombinant vaccine comprising a serotype 9 fowl adenovirus vector (FAdV-9) having at least one exogenous nucleotide sequence inserted encoding at least one antigen of a disease of interest and replacing the adenovirus genome non-essential region, and a pharmaceutically acceptable vehicle, adjuvant and/or excipient, wherein the at least one exogenous nucleotide sequence encoding at least one antigen of a disease of interest and replacing the adenovirus genome non-essential region is located between the 491 and 2782 nucleotides. The vector of this vaccine is stable for industrial scale production. Likewise, even when administering this vaccine in combination with a vaccine against Marek's disease, both vaccines produce an adequate immune response which is not affected by interference between each other. In the same way, effectiveness of the recombinant vaccine is not affected by maternal antibodies, and is capable of inducing both an early and lasting protective response, even with only one application.

Abstract: The present invention includes a live attenuated virus and methods of making the same comprising an isolated virus comprising a viral genome that expresses one or more viral antigens; and one or more exogenous species-specific microRNAs inserted into the viral genome and expressed thereby, wherein the species-specific microRNAs are ubiquitously expressed in a viral target species cell but not in a viral propagation cell.

Abstract: The present invention provides the complete genomic sequence of the epidemic mumps virus (MuV) strain MuVIowa/US/06. Further, a reverse genetics system was constructed and used to rescue recombinant viral constructs that are attenuated compared to rMuVIowa/US/06 and JL vaccine viruses. Such constructs include viral constructs lacking the open reading frame (ORF) of the SH gene (rMuV?SH) and/or incapable of expressing the V protein (rMuV?V).

Abstract: This invention provides a composition comprising an effective amount of glucan capable of enhancing efficacy of antibodies. This invention further provides the above compositions and a pharmaceutically acceptable carrier. This invention also provides a method for treating a subject with cancer comprising administrating the above-described composition to the subject. This invention provides a composition comprising effective amount of glucan capable of enhancing efficacy of vaccines. This invention also provides a method of treating a subject comprising administrating the above pharmaceutical composition to the subject. This invention provides a composition comprising effective amount of glucan capable of enhancing efficacy of natural antibodies. This invention provides a composition comprising effective amount of glucan capable of enhancing host immunity. This invention also provides a composition comprising effective amount of glucan capable of enhancing the action of an agent in preventing tissue rejection.

Abstract: Disclosed herein is a vaccine comprising an antigen and IL-21. Also disclosed herein are methods for increasing an immune response in a subject. The methods may comprise administering the vaccine to the subject in need thereof.

Abstract: Provided is an immunogenic composition comprising 15 different polysaccharide-protein conjugates. Each of the conjugates comprises a capsular polysaccharide prepared from different serotype Streptococcus pneumoniae conjugated to a carrier protein, that is, serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 9N, 9V, 14, 18C, 19A, 19F and 23F. An immunogenic composition formulated into a vaccine comprising an aluminum-based adjuvant increases application range with respect to pneumococcal diseases in infants and children.

Abstract: Disclosed herein are improved compositions and methods involved in treating hematologic cancers, i.e., cancers that begin in blood-forming tissue, such as the bone marrow, or in the cells of the immune system. The compositions comprise complexes containing albumin-containing nanoparticles (e.g., ABRAXANE® nanoparticles) and antibodies. The compositions are used to effect hematologic cancer cell death.

Abstract: The invention encompasses formulations and methods for the production thereof that permit the delivery of concentrated protein solutions. The inventive methods can yield a lower viscosity liquid protein formulation or a higher concentration of therapeutic or nontherapeutic proteins in the liquid formulation, as compared to traditional protein solutions. The inventive methods can also yield a higher stability of a liquid protein formulation.

Abstract: The present invention provides stable pharmaceutical antibody formulations, including liquid drug product formulations and lyophilized drug product formulations, comprising an IgG4 binding agent and a citrate buffer, wherein the pH of the formulation is at or below both pH 6 and the pI of the binding agent. The formulations can be used in the treatment of chronic bowel diseases or rheumatoid arthritis.

Abstract: A method for solubilizing non-polar target compounds into a carrier liquid is described. A carrier oil, such as a MCT, or a mixture of MCTs, may be used to solubilize non-polar target compounds. The carrier oil may also include one or more buffers for stability of the target compounds within the carrier oil.

Abstract: An object is to provide a formulation that includes a particle containing an active ingredient and a surfactant, and a base, and is more excellent in storage stability. For solution, a formulation including a particle containing an active ingredient and a surfactant, and a base, in which the surfactant is contained in a ratio of 5 to 100 parts by weight based on 1 part by weight of the active ingredient, is provided.

Abstract: The present disclosure provides for sustained release pharmaceutical formulations which can deliver both a 5-hydroxytryptamine 3 (5HT3) receptor antagonist and a neurokinin-1 (NK1) receptor antagonist to a subject in need thereof. Formulations described herein are suitable for subcutaneous administration. Also described are methods of treatment of various disorders, including chemotherapy-induced nausea and vomiting (CINV). The disclosed compositions and methods provide for less frequent dosing of the therapeutic agents, thereby increasing subject comfort and compliance.

Abstract: The present invention relates to protein drug conjugates, methods of manufacturing the same and their use in therapy. In particular, the present invention relates to protein drug conjugates comprising a globular protein, an improved linker and a drug for use in targeted drug delivery applications.

Abstract: The present disclosure is directed to core-shell nanoparticles, compositions comprising core-shell nanoparticles, and methods of their use.

Abstract: A peptide-polymer conjugate is provided for use in treating malaria infections, and in particular terminal or drug resistant malaria infections. The conjugate is formed from a polymer to which a peptide having activity against a malaria parasite is co-valently attached. The peptide is a cyclic decapeptide from the closely-related group of tyrocidines, tryptocidines, phenycidines and gramicidin S, and the polymer is a hydrophilic and biocompatible polymer with a terminal thiol, such as poly(N-vinylpyrrolidone) (PVP). The polymer chains can be decorated with a hydrophilic targeting ligand that specifically targets an epitope on red blood cells, and in particular red blood cells infected with a plasmodial parasite. A method for synthesising the peptide-polymer conjugate is also provided.

Abstract: The present invention relates to a method for PEGylating interferon beta.

Abstract: Disclosed are formulations, including both liquid and lyophilized formulations, comprising a benzodiazepine antibody-drug conjugate (ADC) and a cyclodextrin. Also disclosed are methods of purifying mixtures comprising benzodiazepine antibody-drug conjugates and process drug-related impurities.

Abstract: This invention relates to quaternary amine linkers and anti-body drug conjugates thereof, to pharmaceutical compositions containing them, and to their use in therapy for the prevention or treatment of cancer.

Abstract: The present invention relates to a carrier system, a carrier and a pharmaceutical composition comprising a pathogen entry protein or fragment thereof, which specifically binds to a molecule on the surface of a mammalian target cell of said pathogen and which is covalently linked to the surface of said carrier and at least one hydrophilic antipathogenic agent. It further relates to a method of manufacturing a carrier system and the carrier system or the pharmaceutical composition for the use as a medicament.

Abstract: The present invention is directed to protocells for specific targeting of hepatocellular and other cancer cells which comprise a nanoporous silica core with a supported lipid bilayer; at least one agent which facilitates cancer cell death (such as a traditional small molecule, a macromolecular cargo (e.g.

Abstract: Described are nanoparticulates comprising a metallic nanoparticle core and a peptide coating or shell encapsulating the nanoparticle core and being covalently bonded thereto. The coating is formed from a plurality of branched, amphipathic peptides, each comprising a polar/positively charged C-terminal segment, a branch point, and two hydrophobic N-terminal segments extending from the branch point. Methods of forming and using the nanoparticulates are also described. When a plurality of first and second peptides are added sequentially to the nanoparticle core, the peptides they self-assemble to form an interlocking peptide network bilayer where the respective hydrophobic segments of the peptides form beta-sheet structures in which the opposed sequences interlock to form a zipper-like structure in three dimensions.

Abstract: Methods of making and using recombinant AAV virions with decreased immunoreactivity are described. The recombinant AAV virions include mutated capsid proteins or are derived from non-primate mammalian AAV serotypes and isolates that display decreased immunoreactivity relative to AAV-2.

Abstract: Methods and compositions are provided for screening candidate compositions for activity with respect to treatment of aging-associated conditions, e.g., cognitive impairment conditions or age-related dementia. Aspects of the methods include administering a human blood product comprising plasma, to an immunocompromised animal, e.g., a mouse or a rat, and measuring the effect of the product on an endpoint, e.g., neurogenesis, locomotor activity, anxiety, spatial memory, and hippocampus-dependent memory.

Abstract: The present disclosure relates to compounds that are useful as near-infrared fluorescence probes, wherein the compounds include i) a pteroyl ligand that binds to a target receptor protein, ii) a dye molecule, and iii) a linker molecule that comprises an amino acid or derivative thereof. The disclosure further describes methods and compositions for incorporating the compounds as used for the targeted imaging of non-small cell lung cancer (NSCLC) in human subjects. Conjugation of the amino acid linking groups increase specificity and detection of the compound. Methods and compositions for use thereof in diagnostic imaging are contemplated.

Abstract: A dendrimer formation, such as a PAMAM dendrimer or a multiarm PEG polymeric formulation has been developed for systemic administration to the brain or central nervous system. In the preferred embodiment, the dendrimers are in the form of dendrimer nanoparticles comprising poly(amidoamine) (PAMAM) hydroxyl-terminated dendrimers covalently linked to at least one therapeutic, prophylactic or diagnostic agent for treatment of one or more symptoms of neurodegenerative, neurodevelopmental or neurological disorders such as Rett syndrome or autism spectrum disorders, D6 generation dendrimers provide significantly enhanced uptake into areas of brain Injury, providing a means for diagnosis as well, as drug delivery.

Abstract: The present invention includes a device cleaner, and method of use, for cleaning a device port, particularly a medical device port, that may be inserted into the device port cleaner for cleaning and/or disinfecting.

Abstract: A sterilization system having a controllable non-ironing microwave radiation source for providing microwave energy for combining with a gas to produce atmospheric low temperature plasma for sterilizing biological tissue surfaces or the like. A plasma generating region may be contained in a hand held plasma applicator. The system may include an impedance adjustor e.g. integrated in the plasma applicator arranged to set a plasma strike condition and plasma sustain condition. The gas and microwave energy may be transported to a plasma generating region along an integrated cable assembly. The integrated cable assembly may provide a two way gas flow arrangement to permit residual gas to be removed from the surface. Invasive surface plasma treatment is therefore possible. The plasma applicator may have multiple plasma emitters to produce a line or blanket of plasma.

Abstract: Devices, methods, and systems for a luer connector treatment device are described herein. The luer connector treatment device may include one or multiple sources of UV radiation configured to emit UV radiation capable of sterilizing the contents of a treatment chamber while a first medical device (e.g., catheter) is connected to a secondary medical device, and while the first medical device is separate from a secondary medical device. Sources of UV radiation may be located along both a cap and body of the luer connector treatment device.

Abstract: Systems and methods for detecting presence of a thing, the thing treated with a descenter, one method including in an area in which it is possible that a thing treated with a descenter is present, using a detector to detect a descenter level in the area, producing a detected descenter level, comparing the detected descenter level to a normal descenter level for the area, determining that the detected descenter level is different from the normal descenter level, said determining indicating the possible presence of a thing treated with a descenter; and using a trained service animal to facilitate such a method.

Abstract: A method for monitoring cleaning of a surface includes applying an amount of transparent indicator material to an area of a surface and measuring the amount of transparent indicator material remaining on the surface. The transparent indicator material may be fixed on the surface by drying and, when a fluorescent material, may be measured through exposure to ultraviolet radiation.

Abstract: A wax warmer includes a reservoir for receiving a wax melt, a housing defining an interior volume and configured to receive the reservoir, and a hermetically sealed heater engine positioned within the interior volume and in thermal contact with the reservoir.

Abstract: A system for sanitizing and deodorizing garbage chutes using methane sensors in the trash chute that includes an ozone generating unit at the bottom of the trash chute. The system can include an ozone sensor as a safety device to ensure that ozone levels do not surpass a predetermined amount. The present invention works with a controller that controls the ozone generator based on a schedule program for a predetermined time of day. The present invention in an embodiment can include a plurality of additional sensors such as airflow detectors, occupancy detectors and the like.

Abstract: Technologies are generally described for apparatuses and methods relating to a mobile device holder and air freshener. The mobile device holder and air freshener may include a body, a fastening component, a removable cap, a flexible arm, and a mount. The fastening component may secure a mobile electronic device to the apparatus. The removable cap may allow scented material to be installed within the body. The fastening component may secure a mobile electronic device to the apparatus. The flexible arm may be coupled to the body at a first side and the mount on a second side. The mount and the flexible arm may support the mobile electronic device. The body may allow air that has entered the apparatus through a first vent of the apparatus to become scented and flow out of the apparatus through a second vent of the apparatus.

Abstract: The invention relates to an evaporation device for evaporating volatile substances, comprising a container (1) housing a liquid (8) containing the volatile substances, an outlet (2) through which the volatile substances exit and a hole (9) for equalizing the pressure between the inside and the outside of the container, and characterized in that it also comprises a membrane (6) placed between the container (1) and the hole (9), said membrane (6) being leak-tight with respect to said liquid (8) and porous with respect to the gases. This membrane prevents the liquid from accidentally spilling and furthermore solves the issue of balancing pressures inside the container, keeping the rate of evaporation constant until running out of the volatile substances.

Abstract: The disclosure herein concerns a method including receiving at a computer at least one target value of a scent parameter for an environment that is remote from the computer, receiving at the computer a sensed parameter of the environment, and controlling, via the computer, diffusion of a liquid from a source of the liquid in fluid communication with at least one scent diffusion device to achieve the target value of the scent parameter, wherein controlling includes setting or adjusting an operation parameter of the at least one scent diffusion device in response to the sensed parameter.

Abstract: The present invention provides methods and systems for the flexible ion generation device includes at least one dielectric layer, at least one trace having a first end and a second end, the at least one trace is engaged to the at least one dielectric layer, and at least one emitter engaged to the trace for emitting ions.

Abstract: A flexible electrode assembly for an air treatment device comprising: a flexible dielectric layer forming an insulating sheet; a plurality of conductive tracks on a first side of the insulating sheet; a conductive layer on a second side of the insulating sheet; wherein supply of voltage to the conducting tracks and the conductive layer generates plasma which is discharged from the conducting tracks. In a further aspect, the present invention also provides an air treatment apparatus for removal of health threatening airborne pollutants, which may include pathogens, from an air flow, the air treatment apparatus comprising an apparatus having a generally cyclonic-shaped geometry comprising a cylindrical section and a conical section. The present invention also relates to an air treatment device comprising the flexible electrode assembly.

Abstract: A method is provided to accelerate transfer of released body fluids from a body through a treated textile fabric to promote dryness of a skin of the body, the method comprising providing a treated textile fabric facing the body fluids to be transferred, wherein the treated textile fabric includes a first surface and a second surface, wherein the first surface is positioned facing towards the body fluids and the second surface is positioned facing away from the body fluids, wherein the treated textile fabric is structured with a plurality of pores so to allow a passage of a liquid from the first surface to the second surface, and wherein the first surface is coated with a graphene material such that a permeation flux of the first surface is greater than a permeation flux of the second surface.

Abstract: The present chitosan-based superfine fiber invention relates to compositions, formulations, and processes that result in numerous significant advantages for the production and use of superfine fiber bioactive matrices in biomedical applications. The present invention relates to superfine, chitosan-based fibers, wherein the chitosan-based fibers have a percentage chitosan content of at least about 20% w/w, and highly conformable and compliant matrices comprising such fibers, processes for their production, and related formulations. The superfine chitosan-based fibers of the invention preferably include microfibers with diameter less than or equal to about 10 microns and micron and submicron fibers that are about 2 microns and less.

Abstract: An absorbent article comprising a complexed or encapsulated malodor control composition having at least one volatile aldehyde and an acid catalyst, and methods of use thereof, are provided. The malodor control composition is suitable for a variety of absorbent articles, including use in diapers, toddler training pants, adult incontinence garments, sanitary napkins, pantiliners, interlabial devices, hemorrhoid pads, and the like.

Abstract: Provided is a conformable composition for skin application having good formability into a predetermined shape, good conformability to skin, and shape retention after the contact with water such as excretion without loss of its shape. The conformable composition for skin application includes a reinforcing component, a rubber adhesive component, and a hydrophilic polymer compound, or the conformable composition for skin application at least includes 1 to 20 wt % a reinforcing component, 40 to 90 wt % a rubber adhesive component, and 2 to 40 wt % a hydrophilic polymer compound.

Abstract: A bone cement composition contains (a) the product of a polymerisation reaction between a high molecular weight dimethacrylate monomer having a molecular weight of at least 250 and bearing at least one hydrophilic group, a monofunctional methacrylate monomer having a molecular weight of not more than 250 bearing at least one hydrophilic group, an methacrylate monomer, and a polymer having a molecular weight of at least 200,000, and (b) an inorganic filler which is present in an amount of at least about 40% by weight, based on the total weight of the cement composition.

Abstract: The present invention provides an improved tissue adhesive to repair defects in soft tissue. Following ASTM standard tests, crosslinked methacryloyl-substituted gelatin hydrogels of the present invention (GelSEAL) were shown to exhibit adhesive properties, i.e. wound closure strength, shear resistance and burst pressure, that were superior to clinically used fibrin- and poly(ethylene glycol)-based glues. Chronic in vivo experiments in rats proved GelSEAL to effectively seal large lung leakages without additional sutures or staples, presenting improved performance as compared to fibrin and poly(ethylene glycol) glues. Furthermore, subcutaneous implantation in rats revealed high biocompatibility of GelSEAL as evidenced by low inflammatory host response.

Abstract: A method of joining and/or sealing tissues in a surgical procedure or medical treatment, comprising the steps of: (1) applying a matrix protein, a photoactivatable metal-ligand complex and an electron acceptor to a tissue portion; (2) irradiating said tissue portion to photoactivate the photoactivatable metal-ligand complex; thereby initiating a cross-linking reaction of the matrix protein to seal said tissue portion or join said tissue portion to an adjacent tissue portion.

Abstract: Adhesive compositions and patches, and associated systems, kits, and methods, are generally described. Certain of the adhesive compositions and patches can be used to treat tissues (e.g., in hemostatic or other tissue treatment applications), according to certain embodiments.

Abstract: The present invention relates to a long-lasting medical product for protecting or treating a lesion in the gastrointestinal tract. The medical product includes a protective covering, wherein the medical product upon application at and about the site of the lesion adheres to the gastrointestinal tissue and is capable of remaining at and about the site of the lesion for a time sufficient to allow the lesion to heal or be treated.

Abstract: Polar hydrophobic ionic materials and, in particular, polar hydrophobic ionic polyurethanes having a minimum ratio of hydrophobic and anionic components to the remainder of the polymer components are provided that exhibit reduced IgG Fab exposure.

Abstract: A thiol-yne polymeric material and methods for producing said polymers are disclosed. The material is produced by the radically mediated polymerization of monomers having alkyne and thiol functional groups. The alkyne moiety, internal or terminal, may react with one or two thiols. Degradable monomers may be used to form degradable polymers.

Abstract: A method for making a porous devitalised scaffold suitable for use in repair of osseous, chondral, or osteochondral defects in a mammal comprises the steps of providing micronized extracellular matrix (ECM) tissue, mixing the micronized extracellular matrix with a liquid to provide a slurry, and freeze-drying the slurry to provide the porous scaffold. A porous scaffold suitable for use in repair of osseous, chondral, or osteochondral defects in a mammal and comprising a porous freeze-dried matrix formed from micronised decellularised extracellular matrix tissue is also described.